Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook

Core Insights - Fagron reported a solid third-quarter performance with a revenue growth of 6.4%, reaching €228.2 million, and confirmed its full-year revenue outlook of €930 – €950 million for 2025 [1][6][7] Group 1: Financial Performance - The company achieved an organic growth rate of 8.5% at constant exchange rates (CER) on a normalized basis, and 5.7% when accounting for the impact of GLP-1 drug shortages [7] - Revenue for Q3 2025 was €228.2 million, reflecting a 6.4% increase and a 10.3% increase at CER, driven by resilient structural drivers and focused commercial execution [7] Group 2: Regional Performance - EMEA showed broad-based progress across Brands, Essentials, and Compounding Services, with a mix of mature and growth markets responding positively to commercial efforts [3] - Latin America, particularly Brazil, continued strong momentum with targeted commercial activities and product launches supporting increased adoption [4] - North America remains a key growth engine, with planned capacity expansion and successful FDA inspections validating corrective actions [4] Group 3: M&A Activity - The company maintained momentum in mergers and acquisitions (M&A), signing University Compounding Pharmacy to strengthen its health and wellness platform in the U.S. [5] - Antitrust clearance for Purifarma and Injeplast in Brazil marks a significant milestone for expanding Fagron's portfolio and capabilities [5] - A total of eight acquisitions have been announced year-to-date, indicating ongoing strategic growth initiatives [7]